bioMerieux SA · EURONEXT:BIM
bioMerieux SA — FY2020 Earnings Presentation
26 slides from bioMerieux SA's earnings presentation, Feb 24, 2021
Slide 1: FY 2020 Results & 2021 Outlook
FY 2020 Results & 2021 Outlook Investor Presentation – February 24th, 2021 PIONEERING DIAGNOSTICS
Slide 2: Disclaimer
DISCLAIMER This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial, medical and competitive uncertainties in markets addressed by bioMérieu
Slide 3: Agenda
AGENDA OVERVIEW OF bioMérieux FY 2020 ACTIVITY REVIEW FY 2020 FINANCIAL RESULTS CSR AMBITION 2021 OUTLOOK
Slide 4: Key Takeaways – 2020 Performance
KEY TAKEAWAYS – 2020 PERFORMANCE SALES PROFITABILITY BUSINESS TRENDS €3,118m €613m Molecular biology +19.7% 19.6% of sales at constant exchange rates and scope of consolidation vs. 14.5% in 2019 Microbiology Immunoassays FREE CASH FLOW LEVERAGE €328m 0.1x EBITDA Industry 4
Slide 5: Comprehensive COVID-19 In Vitro Diagnostic Solution
COMPREHENSIVE COVID-19 IN VITRO DIAGNOSTIC SOLUTION EXTRACTION PCR TEST SYNDROMIC SEROLOGY ARGENE® SARS-CoV-2 R-GENE® SARS-Cov-2 RESPI R-GENE® VIDAS® EMAG® & BIOFIRE® RP2.1 anti-SARS-CoV-2 IgM EASYMAG® BIOFIRE® RP2.1plus anti-SARS-CoV-2 IgG High quality and fully Ready-to-use kits with internal Rapi
Slide 6: BIOFIRE Leading the Syndromic Market
BIOFIRE® LEADING THE SYNDROMIC MARKET BIOFIRE® +79% BIOFIRE® Key Diagnostic solution GROWTH in the fight against Covid DRIVERS Installed base • BIOFIRE® FILMARRAY® menu from 10,400 to +20% 2020: RP 2.1 & BCID 2 1061 17,300 units +37% 2021: Joint Infection & Pneumonia w/ Covid +50% • Evolutive BI
Slide 7: BIOFIRE Manufacturing Capacity Increase
BIOFIRE® MANUFACTURING CAPACITY INCREASE MANUFACTURING NEW MANUFACTURING PRODUCTION BUILDING Evolution of Monthly Average (K Units) Since July 2020 1,200 AUTOMATION 750 In line with the plan 500 ORGANIZATION 24/7 2019 2020 2021 7
Slide 8: Other Clinical Ranges Impacted by COVID, Recovering in 2nd Semester
OTHER CLINICAL RANGES IMPACTED BY COVID, RECOVERING IN 2ND SEMESTER CLINICAL MICROBIOLOGY IMMUNOASSAYS -5% -7% ORGANIC SALES ORGANIC SALES GROWTH GROWTH • Performance impacted by COVID , but back to • Strong impact of COVID in Q2, since then growth in Q4 on culture media and blood culture stable in
Slide 9: Industrial Microbiology: Performance Impaired by COVID but Solid Fundamentals
INDUSTRIAL MICROBIOLOGY PERFORMANCE IMPAIRED BY COVID BUT SOLID FUNDAMENTALS REMAINS SOLID FUNDAMENTALS +2% ORGANIC SALES • Increasing testing requirements to protect consumers and brands more conscious of their environmental impact GROWTH • Expansion of rapid methods to improve • Performance impact
Slide 10: Agenda
AGENDA OVERVIEW OF bioMérieux FY 2020 ACTIVITY REVIEW FY 2020 FINANCIAL RESULTS CSR AMBITION 2021 OUTLOOK
Slide 11: FY 2020 Sales by Application
FY 2020 SALES BY APPLICATION: Exceptional performance of molecular due to COVID-19 €78m 2% INDUSTRY +2% €1207m MOLECULAR +84% 39% €455m 15% GROUP €3,118m +19.7% €428m 14% €951m IMMUNOASSAYS -7% 30% MICROBIOLOGY -5% Clinical applications (85%) +23% 11
Slide 12: FY 2020 Sales by Geography
FY 2020 SALES BY GEOGRAPHY: Strong momentum in AMERICAS driven by molecular FY 2020 REVENUES €3,118m AMERICAS EMEA ASPAC €1,589m €1,025m €505m 51% of sales 33% of sales 16% of sales ORGANIC GROWTH +37% +8% +0.6% +19.7% 12
Slide 13: FY 2020 Sales
FY 2020 SALES Currency Change in scope of Organic effect consolidation growth + € 527m - € 82m (5) - € 2m €3,118m €2,675m USD (1) - €29m LatAm (2) - €28m +19.7% Asia (3) - €11m Metera (4) - €11m + 16.6% FY 2019 FY 2020 13 (1) Including HKD (2) ARS, BRL, CLP, COP, MXN (3) AUD, CNY, INR, KRW, SGD, THB
Slide 14: FY 2020 P&L
FY 2020 P&L: Contributive Operating Income up 66% like-for-like In €m FY As a % FY As a % % change % change of sales of sales as reported at constant 2020 2019 exchange rates and scope Net sales 3,118 100% 2,675 100% + 16.6% + 19.7% Cost of sales -1,365 -43.8% -1,208 -45.2% + 13.0% + 15.4% Gross pro
Slide 15: FY 2020 Contributive Operating Margin
FY 2020 contributive operating margin: strong leverage of Covid-19 and operational improvement +66% - € 15m - € 9m - € 30m + € 106m € 644m € 613m € 174m 20.6% 19.6% € 389m 14.5% (1) FY 2019 Covid-19 Operational US pension Phantom share FY 2020 at FX FY 2020 impact improvement settlement var. plan va
Slide 16: FY 2020 Consolidated P&L: from Contributive Operating Income to EPS
FY 2020 consolidated P&L: from contributive operating income to EPS In €m FY As a % FY As a % % change of sales of sales as reported 2020 2019 Contributive operating income 613 19.6% 389 14.5% + 57.7% BioFire acquisition related costs - 18 - 18 Other non-recurring expenses - 42 Operating income 553
Slide 17: FY 2020 Tax Rate
FY 2020 tax rate French tax rate 32.0% Foreign & reduced tax rates -7.4% -7.4% Mainly due to US tax rate Tax credits -1.8% -1.8% Mainly R&D Tax Credit FDII (1) -1.4% -1.4% Implemented in 2019 Others (2) +0.8% +0.8% Recurring effective tax rate 22.2% Non-recurring items +1.0% +1.0% Sponsorshi
Slide 18: FY 2020 Cash Flow Statement
FY 2020 cash flow statement Inventory: - €83m In €m FY 2020 FY 2019 Payables: + €5m Receivables: -€80m EBITDA (1) 824 578 Social & tax debts: + €57m Working capital requirement - 86 - 69 Others: + €15m Income tax paid & financial charges - 142 - 102 Other cash flow from operations 11 16 Capex 9% of
Slide 19: Exposure and Sensitivity to Foreign Currencies
Exposure and sensitivity to foreign currencies FX impact of +/- 5% FX variation vs. EUR FX exposure Estimated impact of +/- 5% FX on contributive operating income on revenues variation vs EUR on contributive (2020 basis) operating income (1) USD & related(2) 47% +/- € 15m JPY € 2m 5% Chinese Yuan 7%
Slide 20: Agenda
AGENDA OVERVIEW OF bioMérieux FY 2020 ACTIVITY REVIEW FY 2020 FINANCIAL RESULTS CSR AMBITION 2021 OUTLOOK
Slide 21: A New CSR Ambition to Support Our Long Term Vision
A NEW CSR AMBITION TO SUPPORT OUR LONG TERM VISION HEALTH Lead the fight against infectious diseases through We pioneer in vitro diagnostics the use of IVD innovation, and be the leader in the We are bioMérieux to improve public health worldwide fight against AMR*. WE ACT FOR PLANET Adopt a Science-
Slide 22: Agenda
AGENDA OVERVIEW OF bioMérieux FY 2020 ACTIVITY REVIEW CSR PRIORITIES FY 2020 FINANCIAL RESULTS 2021 OUTLOOK
Slide 23: 2021 Outlook
2021 OUTLOOK +5.0% to +8.0% Uncertain business environment due to covid Revenues at constant exchange rates First half growth aligned with Q4 2020 trend & scope of consolidation Negative FX impact linked to stronger Euro Estimated €30-35m of negative FOREX impacts Contributive Aligned with 2
Slide 24: bioMérieux at the Forefront of the Fight Against Infectious Diseases
bioMérieux at the forefront of the fight against infectious diseases Comprehensive & complementary Increasing recognition of the value of portfolio of technologies and Diagnostics & Molecular solutions solutions Focus on antimicrobial resistance, respiratory diseases, sepsis Solid financial structur
Slide 25: Pioneering Diagnostics
BIOMERIEUX PIONEERING DIAGNOSTICS
Slide 26: Contacts
CONTACTS Ordinary shares (EUR) Franck ADMANT ISIN: FR0013280286 Investor Relations bioMérieux is listed on Euronext Paris [email protected] Reuters: BIOX.PA / Bloomberg: BIM.FP American Depository Receipt (1:0.1 USD) Follow us on: Reuters: BMXXY.PK / Bloomberg: BMXXY.US www.biomerieux.com